BIO Comments on FDA's Guidance on Consultation Procedures: Foods Derived from New Plant Varieties
February 9, 2017
BIO submitted comments to the Food and Drug Administration (FDA) on its request for input on a public notice, Guidance on Consultation Procedures: Foods Derived from New Plant Varieties.
BIO applauds FDA’s work to develop and enforce a sensible, science-based approach to the regulation of products of agricultural biotechnology. FDA’s consultation process has worked well for nearly 30 years, and BIO members do not consider the current information requests to be unduly burdensome.
However, BIO strongly encourages the FDA to identify mechanisms to better incorporate its experience over time and, where possible, implement more efficient, streamlined review processes for products similar to ones the agency has reviewed in the past as well as products reviewed by the Center for Food Safety and Nutrition (CFSAN) and the Center for Veterinary Medicine (CVM).
Phyllis Arthur, EVP, Health Policy and Programs, “Vaccines are one of the most important and effective innovations for the defense of public health. They have saved millions of lives and drastically reduced or eliminated deadly and debilitating…
Re: Docket No. CDC-2025-0454; Advisory Committee on Immunization Practices (ACIP)The Biotechnology Innovation Organization (BIO) is appreciative of the opportunity to provide comments to the Advisory Committee on Immunization Practices (ACIP) in…
Dear Majority Leader Thune, Minority Leader Schumer, Speaker Johnson, and Minority Leader Jeffries:The Council of State Bioscience Associations (CSBA) is a coalition of independent state and territory based non-profit trade associations, each of…
BIO submitted comments to the Food and Drug Administration (FDA) on its request for input on a public notice, Guidance on Consultation Procedures: Foods Derived from New Plant Varieties.
BIO applauds FDA’s work to develop and enforce a sensible, science-based approach to the regulation of products of agricultural biotechnology. FDA’s consultation process has worked well for nearly 30 years, and BIO members do not consider the current information requests to be unduly burdensome.
However, BIO strongly encourages the FDA to identify mechanisms to better incorporate its experience over time and, where possible, implement more efficient, streamlined review processes for products similar to ones the agency has reviewed in the past as well as products reviewed by the Center for Food Safety and Nutrition (CFSAN) and the Center for Veterinary Medicine (CVM).